Purpose: Hydration and urinary alkalinization are essential for reducing renal dysfunction with high dose methotrexate (HDMTX). This report presents an analysis of institutional methods used to achieve adequate urinary alkalinization and output for patients receiving single agent HDMTX. Renal and metabolic parameters of tolerance were examined.
Methods: Medical records of adult patients receiving HDMTX during the calendar years of 2008–2009 were retrospectively reviewed to determine the time to achieve urine pH > 7. Number of hospital days, bicarbonate dose, ordered hydration rate, urine output, and urine pH were assessed. A survival analysis model was run for time to urine pH > 7 using preadmission oral bicarbonate as a predictor variable and including a frailty term. Observational statistics were performed for other parameters.
Results: The analysis included 79 encounters for ten patients. Urine pH > 7 was achieved more rapidly in patients receiving preadmission oral bicarbonate (P = 0.012). The number of patients receiving HDMTX on the same day as admission was greater for those receiving preadmission oral bicarbonate (47%) in comparison to those who did not (2%), and they spent less time in the hospital. A standard regimen for hydration and urinary alkalinization based on this project is reported. The nature and frequency of adverse events were as expected for this treatment.
Conclusion: At our institution, the time to achieve urinary alkalinization was reduced for patients receiving preadmission oral bicarbonate which facilitated chemotherapy infusion on the same day as admission and decreased the number of calendar days that patients stayed in the hospital.
WidemannBCAdamsonPC. Understanding and managing methotrexate nephrotoxicity. Oncologist2006; 11: 694–703.
4.
PlotkinSRBetenskyRAHochbergFH. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res2004; 10: 5643–5646.
5.
JahnkeKKorfelAMartusP. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol2005; 16: 445–449.
6.
ZhuJJGerstnerEREnglerDA. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-Oncol2009; 11: 211–215.
7.
CobertJHochbergEWoldenbergNHochbergF. Monotherapy with methotrexate for primary central nervous system lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort. JNeurooncol2010; 98: 385–393.
R Foundation for Statistical Computing. ‘R: A Language and Environment for Statistical Computing’, http://www.R-project.org (accessed 23 March 2011).
10.
BatchelorTCarsonKO’NeillA. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96 – 07. J Clin Oncol2003; 21: 1044–1049.
11.
HerrlingerUKukerWUhlM. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol2005; 57: 843–847.
12.
KiewePFischerLMartusPThielEKorfelA. Primary central nervous system lymphoma: monocenter, long term, intent to treat analysis. Cancer2008; 112: 1812–1820.
13.
SilvaniASalmaggiAEoliM. Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. J Neurooncol2007; 82: 273–279.
14.
WatanabeTKatayamaYYoshinoA. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neuro Oncol2003; 63: 87–95.
15.
BarrettKEBarmanSMBoitanoSBrooksH. Acidification of the urine & bicarbonate excretion. In: BarrettKEBarmanSMBoitanoSBrooksH (eds) Ganong’s review of medical physiology, Chapter 40, 23e, http://www.accessmedicine.com/content.aspx?aID=5244356 (accessed 8 June 2011).
